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Abstract: Recommendations for zinc intake during childhood vary widely across Europe. 
The EURRECA project attempts to consolidate the basis for the definition of micronutrient 
requirements, taking into account relationships among intake, status and health outcomes, 
in order to harmonise these recommendations. Data on zinc intake and biomarkers of zinc 
status reported in randomised controlled trials (RCTs) can provide estimates of dose-response 
relationships which may be used for underpinning zinc reference values. This systematic 
review included all RCTs of apparently healthy children aged 1–17 years published   
by February 2010 which provided data on zinc intake and biomarkers of zinc status.   
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An intake-status regression coefficient (   ) was calculated for each individual study and 
calculated the overall pooled     and SE (   ) using random effects meta-analysis on a double 
log scale. The pooled dose-response relationship between zinc intake and zinc status 
indicated that a doubling of the zinc intake increased the serum/plasma zinc status by 9%. This 
evidence can be utilised, together with currently used balance studies and repletion/depletion 
studies, when setting zinc recommendations as a basis for nutrition policies. 
Keywords: zinc; children; serum zinc; systematic review; dose-response; dietary 
recommendations; EURRECA 
 
1. Introduction 
Suboptimal dietary zinc intake is increasingly recognised as an important public health issue. 
Although the lack of generally accepted biomarkers of zinc status has impeded estimation of the global 
prevalence of zinc deficiency, based on information regarding the amount of zinc present in national 
food supplies, it has been estimated that the risk of low dietary intake of absorbable zinc and 
consequent zinc deficiency affects between one-third and one-half of the world’s population [1] and 
rates of deficiency may approach 73% in some regions [2]. Although severe zinc deficiency is 
uncommon in European populations, marginal deficiency is likely to be much more prevalent [3], with 
associations to immune system dysfunction and restricted physical development [4]. Children are 
particularly vulnerable to suboptimal zinc status during periods of rapid growth that create increased 
zinc needs that may not be met [5,6]. It is estimated that over 450,000 deaths per year (4.4% of  
all mortalities) among children between six months and five years of age are attributable to zinc 
deficiency [7]. Zinc deficiency also has an impact of child morbidity, impairing growth and 
contributing to childhood stunting [8,9].  
Physiological requirements for zinc peak at the time of the pubertal growth spurt, the onset of which 
varies according to gender. In girls the onset of the growth spurt (OGS) occurs at 10.1 years and peak 
height velocity (PHV) occurs at 12.0 years. In boys OGS and PHV occur at 11.8 and 14.2 years, 
respectively [10]. Even after the growth spurt has ceased, adolescents may require additional   
zinc to replete tissue zinc pools depleted during puberty [11]. Marginal zinc status during the pubertal 
growth spurt has been associated with slower skeletal growth, maturation, and reduced bone 
mineralisation [12–14]. As nearly a third of total skeletal mineral is accumulated in the 3–4 year period 
immediately after the onset of puberty [15] suboptimal zinc intake may have long-term consequences 
on bone health.  
Although a sensitive and specific biomarker has yet to be identified, a recent systematic review 
concluded that plasma (or serum) zinc concentration was responsive to both zinc supplementation and 
depletion and is the most widely used biomarker for zinc [16]. However, meta-analytic methods have 
not yet been used to model zinc status as a function of zinc intake levels. Understanding the relationship 
between dietary intake and micronutrient status is essential for deriving dietary recommendations.  
The recommendations for zinc intake during childhood vary widely across Europe and comparisons 
are difficult due to differences in categorisation. For example between 4 and 6 age categories are used Nutrients 2012, 4  843 
 
 
to describe micronutrient recommendations in childhood with different age cut-off points being used 
by different European countries [17,18]. Recommendations for zinc intake differ between males and 
females at the age of 15 years in most countries, but also differ at the age of 10 years in some countries. 
Zinc intake values range from 2.9 to 10.0 mg/day in children aged 5 years, 5.7 to 15.5 mg/day (boys)  
and 4.6 to 15.0 mg/day (girls) in children aged 10–15 years [17]. The EURRECA project attempts to 
consolidate the basis for the definition of micronutrient requirements across Europe, taking into account 
relationships among intake, status and health outcomes, in order to harmonise these recommendations [19]. 
This paper presents a systematic review of the data from all available randomised controlled trials 
(RCTs) meeting EURRECA’s quality standard [20], which investigated zinc intake and biomarkers of 
zinc status, and combines these studies in meta-analyses to model zinc concentrations in serum or 
plasma as a function of zinc intake.  
2. Methods 
2.1. Search Strategy 
This research was conducted within the framework of the European Micronutrient Recommendations 
Aligned (EURRECA) Network of Excellence that aims to identify the micronutrient requirements for 
optimal health in European populations (EURRECA [21]). This review was part of a wider review 
process to identify studies assessing the effect of zinc intake on different outcomes (biomarkers of zinc 
status and health outcomes). The wider searches were performed of literature published up to and 
including February 2010 using MEDLINE, Embase, and Cochrane using search terms for “study 
designs in humans” and “zinc” and “intake OR status”. Both indexing and text terms were used and 
languages included were restricted to those spoken in the EURRECA Network (English, Dutch, 
French, German, Hungarian, Italian, Norwegian, Polish, Spanish, Greek, and Serbian). The full Ovid 
MEDLINE search strategy can be found in Table 1. Reference lists of retrieved articles and published 
literature reviews were also checked for relevant studies. Authors were contacted to request missing 
data or clarify methods or results. The search process is illustrated in Figure 1. 
Table 1. Search strategy: MEDLINE February 2010 [22].  
No. Search  Term  Results 
1  randomised controlled trial.pt.  280,821 
2  controlled clinical trial.pt.  79,998 
3 randomised.ab.  196,604 
4 placebo.ab.  117,891 
5  clinical trials as topic.sh.  146,242 
6 randomly.ab.  145,491 
7 trial.ab.  203,467 
8 randomised.ab.  38,423 
9  6 or 3 or 7 or 2 or 8 or 1 or 4 or 5  734,511 
10  (animals not (human and animals)).sh.  4,482,479 
11  9 not 10  642,665 
12  (cohort* or “case control*” or cross-sectional* or “cross sectional” or case-control* 
or prospective or “systematic review*”).mp. 
768,885 Nutrients 2012, 4  844 
 
 
Table 1. Cont. 
13  exp meta-analysis/ or expmulticenter study/ or follow-up studies/ or prospective 
studies/ or intervention studies/ or epidemiologic studies/ or case-control studies/ or 
exp cohort studies/ or longitudinal studies/ or cross-sectional studies/ 
1,013,635 
14 13  or  12  1,203,767 
15 14  not  10  1,154,385 
16 11  or  15  1,599,094 
17  ((zinc or Zn or zinc sulphate or zinc gluconate or zinc acetate or methionine or zinc 
isotope*) adj3 (intake* or diet* or supplement* or deplet* or status or serum or 
plasma or leukocyte or concentration* or expos* or fortif* or urine or hair)).ti,ab. 
16,681 
18  Nutritional Support/ or Dietary Supplements/ or nutritional requirements/ or Breast 
feeding/ or exp infant food/ or bottle feeding/ or infant formula/ 
63,098 
19  exp Nutritional Status/ or exp Deficiency Diseases/ or supplementation/ or diet 
supplementation/ or dietary intake/ or exp diet restriction/ or exp mineral intake/ or 
Diet/ or Food, Fortified/ or nutrition assessment/ or Nutritive Value/ 
176,014 
20  (intake* or diet* or supplement* or deplet* or status or serum or plasma or 
leukocyte or concentration* or expos* or fortif* or urine or hair).ti,ab. 
3,166,092 
21  18 or 19 or 20  3,263,114 
22 zinc/  41,027 
23 22  and  21  20,745 
24 23  or  17  26,943 
25 24  and  16  2410 
2.2. Criteria for the Consideration of Studies for This Review 
Included studies were RCTs in apparently healthy child (human) populations aged from 1 to 17 years 
that supplied zinc supplementation either as capsules or part of a fortified meal. If supplemental zinc 
was provided as a component of a fortified meal, studies were only considered acceptable if zinc was 
the only constituent that was different between treatment groups. Only studies that measured zinc 
status as serum or plasma zinc were included; and those that reported sufficient data or had sufficient 
data obtainable from the authors to estimate     and SE (   ) for the assumed linear relation on the loge–loge 
scale. Studies were excluded if they were a group RCT (community trial), or were commentaries, 
reviews, or duplicate publications from the same study. Studies were excluded if children were 
hospitalised, had severe protein-energy malnutrition or a chronic disease or if supplemental zinc was 
provided for less than 6 weeks. 
2.3. Selection of Articles 
Of 4719 identified articles in the wider search on zinc intake, status and priority health outcomes in 
all populations, 2557 were excluded based upon screening of the title and abstract. Two independent 
reviewers screened 10% of the abstracts in duplicate and any discrepancies were discussed before 
screening the remaining references. Following subdivision into appropriate population groups the full 
texts of the 328 manuscripts were assessed to determine inclusion and exclusion by two independent 
reviewers and disagreements rectified through discussion. 302 studies were excluded because they did 
not meet the inclusion criteria. Of the remaining 26 studies, 8 studies were excluded as they had not Nutrients 2012, 4  845 
 
 
investigated the relation between zinc intake and zinc related biomarkers, but related either intake or 
status directly to a health endpoint. For the purpose of this paper, 18 RCTs remained. Table 2 presents 
the characteristics of the included studies. 
Figure 1. Study selection process for systematic review (* some papers reported more than 
one relationship). 
 
2.4. Data Extraction 
For each of the identified manuscripts, data was extracted independently by two reviewers into a 
standardised database. Extracted data included population characteristics, dose of elemental zinc in 
intervention and placebo supplements, duration of the study, dietary intake of zinc, and mean 
concentration of zinc in plasma or serum at the end of the intervention period. Serum/plasma zinc 
concentrations were converted to µmol/L when applicable. 
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Table 2. Summary of included trials reporting the effect of dietary zinc intake on serum/plasma zinc status in children. 
First Author, 
Year, Country 
Participants Treatment  Groups  (n) 
Mean Zn 
Intake 
(mg/day)
Mean (SD)  
Plasma/Serum Zn 
(µmol/L) 
Duration 
Zinc Status 
Biomarker 
[Analytical Method]
Main Results 
Mahloudji, 1975, 
Iran [23] 
Males & females  
aged 6–12 years 
Fe only (12);  
Fe + 20 mg/day Zn (13) 
5.65;  
25.65 
8.95 (1.80) 
8.50 (1.93) 
8 months  Plasma Zn [AAS]  No significant difference between plasma Zn of the 
supplemented and placebo groups 
Hambidge, 1979, 
USA [24] 
Males & females  
aged 33–90 months  
Male placebo (15);  
Male Zn FM 2.57 mg/day (20); 
Female placebo (14);  
Female Zn FM 2.57 mg/day (11) 
6.3;  
9.27;  
6.3;  
9.27 
11.06 (2.23) 
11.85 (2.23) 
10.61 (1.81) 
11.96 (1.81) 
9 months  Plasma Zn [AES]  Plasma Zn significantly higher in Zn supplemented 
compared to placebo (girls and combined sexes only  
p < 0.05) 
Walravens, 
1983, USA [25] 
Males & females  
aged 2–6 years  
Placebo (16);  
10 mg/day Zn (16) 
4.6;  
15.9 
11.32 (2.14) 
10.86 (2.14) 
12 months  Plasma Zn [AES]  No significant difference between plasma Zn of the 
supplemented and placebo groups 
Gibson, 1989, 
Canada [26] 
Males aged  
59–95 months  
Placebo (21);  
10 mg Zn/day (18)  
6.4;  
16.7 
15.8 (3.5) 
17.9 (3.4) 
6 months  Serum Zn [AAS]  No significant correlation between serum Zn and dietary 
Zn levels  
Cavan, 1993, 
Guatemala [27] 
Males & females,  
mean age  
81.5 (±7.0) months 
1 
Placebo (74);  
10 mg Zn/day (71)  
5.65;  
15.65 
14.9 (2.1) 
16.2 (2.9) 
25 weeks  Plasma Zn [AAS]  Plasma Zn significantly higher in Zn supplemented 
compared to placebo (p < 0.01) 
Friis, 1997, 
Zimbabwe [28] 
Males and females 
aged 11–17 years  
Placebo (121);  
30–50 mg/day Zn (122) 
5.65;  
45.65 
2 
10.89 (2.5) 
11.71 (2.4) 
12 months  Serum Zn [AAS]  The decline in zinc concentration was significantly lower 
in the Zn supplemented group compared to the placebo 
group (p < 0.02) 
Rosado, 1997, 
Mexico [29] 
Males & females  
aged 18–36 months 
Placebo (55);  
20 mg Zn/day (54) 
5.65;  
25.65 
14.4 (4.45) 
16.8 (5.88) 
12 months  Plasma Zn [AAS]  Plasma Zn increased significantly in the Zn supplemented 
group over the 12 months period (p < 0.01) 
Ruz, 1997,  
Chile [30] 
Males & females  
aged 27–50 months  
Placebo (33);  
10 mg/day Zn (36) 
6.4;  
17.1 
17.7 (1.9) 
17.6 (2.2) 
6 months  Plasma Zn [AAS]  No significant difference between plasma Zn of the 
supplemented and placebo groups 
Sandstead, 1998, 
China [31]  
(3 regions) 
Males & females  
aged 6–9 years 
Chonqing MN, no Zn (35); 
20 mg/day Zn + MN (35);  
Quindgdao MN, no Zn (36);  
20mg/day Zn + MN (36);  
Shanghai MN, no Zn (37);  
20 mg/day Zn + MN (37) 
5.65;  
25.65; 
5.65;  
25.65;  
5.65;  
25.65 
19.83 (4.12) 
23.6 (4.12) 
20.42 (4.08) 
22.97 (4.08) 
17.9 (2.75) 
17.97 (2.75) 
10 weeks  Plasma Zn [AAS]  Plasma Zn significantly higher in Zn supplemented 
compared to placebo (p < 0.05) in Chonqing and 
Quindgdao groups. Nutrients 2012, 4  847 
 
 
Table 2. Cont.  
Clark, 1999,  
UK [32] 
Peripubertal 
females, mean age 
12.2 (±0.3) years 
Placebo (19);  
15 mg Zn/day (23) 
6.6;  
21.6 
12.6 (1.0) 
16.7 (4.9) 
6 weeks  Serum Zn  
[no method given] 
Serum Zn significantly higher in Zn supplemented 
compared to placebo (p < 0.001) 
Smith, 1999,  
Belize [33] 
Males & females  
aged 22–66 months  
Placebo (10);  
70 mg Zn/day (12) 
5.65;  
75.65 
11.7 (0.68) 
13.5 (0.68) 
6 months  Serum Zn [AAS]  Serum Zn significantly higher in Zn supplemented 
compared to placebo (p < 0.001) 
Munoz, 2000, 
Mexico [34] 
Males & females  
aged 18–36 months  
Placebo (54);  
20 mg/day Zn (47) 
5.65;  
25.65 
14.3 (4.7) 
16.8 (5.6) 
6 months  Plasma Zn [AAS]  Serum Zn significantly higher in Zn supplemented 
compared to placebo (p < 0.0001) 
Lopez de Romana, 
2005, Peru [35] 
Males & females  
aged 3–4 years 
Fe FM (12);  
Fe + 3 mg/day Zn FM (10); 
Fe + 9 mg/day Zn FM (12); 
4.71;  
8.72;  
15.7 
11.87 (1.88) 
11.65 (1.25) 
12.60 (1.51) 
70 days  Plasma Zn [ICP-MS]  No significant differences in plasma Zn were found 
between treatments 
Silva, 2006,  
Brazil [36] 
Males & females 
aged 12–59 months 
3 
Placebo (30);  
10 mg/day Zn (28)  
5.65;  
15.65 
8.0 (0.58) 
13.4 (0.25) 
4 months  Serum Zn [AAS]  Serum Zn significantly higher in Zn supplemented 
compared to placebo (p < 0.05) 
Sandstead, 2008, 
USA (Mexican 
Americans) [37] 
Males & females  
aged 6–7 years 
MN, no Zn (25);  
20 mg/day Zn + MN (25) 
5.65;  
25.65 
15.4 (1.5) 
15.6 (1.2) 
10 weeks  Plasma Zn [AAS]  Mean plasma Zn increased significantly in both 
groups compared to baseline (p < 0.05) 
Wuehler, 2008, 
Ecuador [38] 
Males & females  
aged 12–30 months 
Placebo (56);  
3 mg Zn/day (50);  
7 mg Zn/day (52);  
10 mg Zn/day (54) 
5.65;  
8.65;  
12.65;  
15.65 
10.6 (1.6) 
12.3 (1.6) 
13.3 (1.7) 
14.0 (1.7) 
4 
6 months  Plasma Zn [ICP-MS]  The mean change in plasma zinc concentrations from 
baseline increased progressively with higher doses of 
supplemental Zn (p < 0.001) 
de Oliveira, 2009, 
Brazil [39] 
Pubescent males, 
mean age  
13 (±0.4) years  
Placebo (26);  
22 mg Zn/day (21) 
5.65;  
27.65 
16.9 (2.1) 
18.7 (3.5) 
12 weeks  Plasma Zn [ICP-MS]  Plasma Zn significantly higher in Zn supplemented 
compared to placebo (p < 0.05) 
Uckarde, 2009, 
Turkey [40] 
Males & females  
aged 8–9 years  
Placebo (109);  
15 mg/day Zn (109) 
5.65;  
20.65 
19.19 (1.80) 
19.50 (2.41) 
10 weeks  Serum Zn [CS]  Both supplemented and placebo groups had 
significantly higher serum Zn at follow up (p < 0.05) 
AAS, atomic absorption spectroscopy; AES, atomic emission spectroscopy; ICP-MS, inductively coupled plasma mass spectrometry; CS, caloric spectrophotometry; MN, micronutrients; 
FM, fortified meal; 
1 all participants also received MN supplements; 
2 children weighing <29.5 kg were given 30 mg Zn/day and those >29.5 kg were given 50 mg Zn/day, this figure is an 
average of the two doses; 
3 all participants also received Fe fortified milk; 
4 geometric means. 
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2.5. Data Synthesis 
One study that included two zinc-treated groups and two control groups (males and females) was 
treated as two independent estimates in the analysis [24] and one study that included three zinc-treated 
groups and three control groups (from different regions of China) [31] and was treated as three 
independent estimates in the analysis. Where studies provided outcome data for two or more   
zinc-treated groups they were included as separate estimates in the meta-analysis [35,38]. In one study 
zinc status was measured at 6 months and 12 months in the same population [26] and only the measure 
at 6 months was used in the analysis (where n was the largest). If dietary intake of zinc (in addition to 
the intervention) was not reported we imputed a value of 5.65 mg/day, the mean dietary intake level  
of the RCTs (n = 7) that did report dietary zinc intake. As mean baseline serum/plasma zinc 
concentrations were infrequently reported, the serum/plasma zinc concentrations in the control group 
of the RCTs were used as a proxy of the baseline serum/plasma zinc concentrations for our analyses.  
2.6. Pre-Specified Potential Factors Modifying the Association  
A pooled meta-analysis was performed combining the evidence from all the available RCTs.   
In addition, we investigated whether age, dose of zinc, duration of the supplementation, and type of 
supplement (zinc only vs. zinc with other micronutrients) were variables that modified the association.  
2.7. Statistical Analyses 
As we wanted to estimate the dose-response relation between zinc intake and serum/plasma zinc, 
the data presented in the studies had to be transformed to a common statistic, namely a regression 
coefficient (   ) and the standard error (SE (   )) of this regression coefficient. The transformations used 
to derive this common single-study estimate from the available summary statistics per study have been 
described elsewhere [41]. In short, we estimated an intake-status regression coefficient (   ) for each 
individual study, based on the assumption of a linear relation on the loge–loge-scale (natural logarithm 
of intake vs. natural logarithm of status). This shape of this linear relationship on the loge–loge-scale 
corresponds to a monotonic concave function on the original scale for β < 1. This shape is assumed to 
be realistic for the biological relationship between zinc intake and plasma/serum zinc concentrations. 
As the true dose-response curve is unknown, this approximation provides a practical methodology to 
estimate the dose-response relationship. We calculated the overall pooled     and SE (   ) using random 
effects meta-analysis, which estimates the between-study variance using the method of DerSimonian 
and Laird and used this estimate to modify the weights used to calculate the summary estimate. 
Residual heterogeneity between studies was evaluated using the I
2 statistic. Pre-specified potential 
factors that could modify the association were explored using stratified random effects meta-analyses. 
The statistical transformations to obtain    ’s and SE (   )’s were performed using GenStat version 13-SP2 
(VSN International Ltd. [42]) and the meta-analysis was performed using STATA version 11.0 
(College Station, TX, USA), with statistical significance defined as p < 0.05. Nutrients 2012, 4  849 
 
 
2.8. Assessment of Risk of Bias in Included Studies 
In order to assess the quality of the included studies and the risk of bias, indicators of internal 
validity were collected during data extraction (Table 2). Based on the indicators two independent 
reviewers assessed the overall risk of bias and disagreements resolved by discussion. The criteria for 
judging these indicators were adapted from the Cochrane Handbook for Systematic Reviews [43]. 
3. Results 
Twenty-four estimates of zinc intake and serum/plasma zinc status in 18 RCTs with children were 
eligible for meta-analysis. All studies were RCTs published between 1975 and 2009 which reported 
zinc intake and plasma/serum zinc concentrations. The 24 estimates included 1722 participants in total 
with sample sizes ranging from 10 to 122. The median duration of the trials was 24 weeks (range  
6–52 weeks). In 11 studies zinc was supplemented alone at doses ranging from 3 to 70 mg/day and in  
7 studies participants also received other micronutrients. Zinc was provided with iron supplements [23] 
or iron fortified milk [36], as part of a fortified meal [24,35], and with other micronutrients [27,31,37]. 
The zinc dose ranged from 10 to 20 mg/day when combined with other vitamin/minerals and 2.57 to 
9 mg/day when provided in fortified meals. Most studies (n = 7) provided the zinc supplements in the 
form of zinc sulphate, but others used zinc citrate [32], zinc gluconate [33], zinc carbonate [23], zinc 
methionine [29,34], amino acid chelate [27], and elemental zinc in a syrup [28,40]. Studies were 
conducted in Latin America (n = 9), North America (n = 4), Asia (n = 3), Africa (n = 1) and Europe  
(n = 1). Habitual zinc intakes ranged from 4.6 to 7.1 mg/day (where data was provided) and ages of 
children ranged from 2 to 17 years. Most studies included, but did not differentiate between, males and 
females, but one study provided separate male and female data [24], one included only females [32], 
and one only males [39]. 
The majority of studies (n = 13) reported that zinc supplementation significantly increased zinc 
plasma/serum status or significantly reduced the decline in zinc serum values compared to placebo.  
Of these, two studies also reported increased plasma/serum zinc concentrations in the placebo group. 
Five studies failed to find a significant relationship between zinc supplementation and zinc 
status  [23,25,26,30,35], four of which provided zinc supplements or fortified meals with a zinc 
concentration of 10 mg/day or less. 
Our meta-analysis of available studies suggested that zinc supplementation was associated with 
increased serum/plasma zinc concentrations. Combining the 18 RCTs in one meta-analysis yielded an 
overall pooled β-coefficient of 0.12 (95% CI 0.04, 0.20; p < 0.005; I
2 97.6%) (Figure 2). Since we 
applied a base-e logarithmic transformation on the zinc intake and serum/plasma zinc concentration 
before calculation of the study-specific    ’s, the overall     represents the difference in the loge transformed 
predicted value of serum/plasma zinc status for each one-unit difference in the loge transformed value 
in zinc intake. Therefore, an overall      of 0.12 means that for every doubling in zinc intake, the 
difference in zinc serum or plasma concentration is 2    (2
0.12 = 1.09), which is 9%. This means that a 
person with a zinc intake of 14 mg/day has a zinc serum/plasma concentration that is 9% higher than a 
person who has a zinc intake of 7 mg/day.  Nutrients 2012, 4  850 
 
 
Figure 2. Random effects meta-analyses of RCTs evaluating the effect of dietary zinc on 
serum/plasma zinc in children. Beta’s represent the regression coefficients for the linear 
association between loge transformed zinc intake and loge transformed serum/plasma zinc 
status (lines represent the confidence intervals of each study). 
 
As the physiological requirements for zinc peak at the time of the pubertal growth spurt, which 
generally occurs in girls between 10 and 15 years and in boys between 12 and 15 years, a separate 
subgroup analysis compared zinc intake and status according to age. As the onset of puberty was rarely 
assessed in papers, arbitrary age groups of <10 year, and ≥10 year were used. One study for which 
mean serum/plasma zinc values were given for children whose ages spanned both age groups were 
excluded from this analysis [23]. A meta-analysis of 18 studies performed in children under 10 years 
yielded an overall β of 0.13 (95% CI 0.04, 0.22; I
2 69.7%), compared to a meta-analysis of 3 studies 
performed in children over 10 years which yielded a β of 0.08 (95% CI 0.02, 0.15; I
2 97.9%), although 
care should be taken with interpreting this finding as the latter analysis is based on limited available data. 
There is statistical evidence for substantial between-study heterogeneity in the overall meta-analysis 
(I
2 97.6%, p < 0.0001). To evaluate potential sources of heterogeneity, the variables duration, age, dose 
of zinc, and zinc status of the placebo groups (as a proxy for baseline zinc status) were added 
simultaneously to a meta-regression model as continuous variables. The analysis revealed that only 
zinc status of the placebo group was a statistically significant determinant of the overall β. The model 
NOTE: Weights are from random effects analysis
Overall  (I-squared = 97.6%, p = 0.000)
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explained 26.5% of between-study variance but the residual variation due to heterogeneity remained 
high (91.7%). It is important to note that serum/plasma zinc levels of the placebo groups were used as 
a proxy of baseline serum/plasma zinc as the mean baseline serum/plasma zinc levels were infrequently 
reported in the papers, however it does suggest that the β vary according to zinc status. 
Table 3 summarises the internal validity of the included studies, assessed as described in the 
methods section. The risk of bias was high in all but three where the risk was low/moderate [25,37,38]. 
Papers were given a high risk of bias rating due to insufficient information provided on sequence 
generation and/or allocation, drop-outs and funding bodies. 
Table 3. Assessment of validity of included RCTs reporting zinc intake and serum/plasma 
zinc in children (adapted from the Cochrane Handbook [43]). 
Author, Year 
Adequate 
Sequence 
Generation 
Allocation 
Concealment 
Adequate 
Blinding 
Adequate 
Dropouts Adequate 
and Outcome  
Data Complete 
Funder 
Adequate 
Lack of other 
Potential Threats 
to Validity 
Overall Risk 
of Bias 
Mahloudji, 1975 [23]  Unclear  Yes  Unclear Unclear  Yes Unclear  High 
Hambidge, 1979 [24]  Unclear  Unclear Yes  Unclear  No  Unclear  High 
Walravens, 1983 [25]  Unclear  Yes  Yes  Yes  Yes  Yes  Moderate 
Gibson, 1989 [26]  Unclear  Yes  Yes  Yes  No  Yes  High 
Cavan, 1993 [27]  Unclear  Yes  Yes  Unclear  Yes  No  High 
Friis, 1997 [28]  Unclear  Yes  Yes  Yes  Yes  Yes  High 
Rosado, 1997 [29]  Unclear  Yes  Yes  Unclear  Yes  Yes  High 
Ruz, 1997 [30]  Unclear  Yes  Yes  Unclear  Yes  Yes  High 
Sandstead, 1998 [31]  Unclear  Unclear Yes  Unclear  No  No  High 
Clark, 1999 [32]  Yes  Yes  Yes  Unclear  No  Unclear  High 
Smith, 1999 [33]  Unclear  Unclear Unclear  Yes  Yes  Yes  High 
Muñoz, 2000 [34]  Unclear  No  Yes  Yes  Nor  Yes  High 
Lopez de Romana, 2005 [35]  Unclear  Unclear  Unclear  Yes  Yes  Yes  High 
Silva, 2006 [36]  Unclear  Unclear  No  Yes  No  Yes  High 
Sandstead, 2008 [37]  Yes  Yes  Yes  Unclear  No  Yes  Moderate 
Wuehler, 2008 [38]  Yes  Unclear  Yes  Yes  Yes  Yes  Low 
de Oliveira, 2009 [39]  Unclear  Unclear No  Unclear  No  Yes  High 
Uckarde, 2009 [40]  Unclear  Yes  Yes  Yes  No  Yes  High 
4. Discussion 
This study is unique in providing an estimate of the dose-response relationship of zinc intake and 
serum/plasma zinc concentrations in children aged 1–17 years. Similar to findings published in an 
earlier systematic review [44], this meta-analysis of 24 estimates in 18 RCTs found a significant effect 
of zinc intake and serum/plasma zinc concentrations in children. In addition we have provided an 
estimate of the dose-response relationship between zinc intake and serum/plasma concentrations. An 
overall     of 0.12 means that for every doubling in zinc intake, the difference in zinc serum or plasma 
concentration is 9%. In other words, a child with a zinc intake of 14 mg/day has a zinc serum/plasma 
concentration that is 9% higher than a person who has a zinc intake of 7 mg/day. It is important to  
note however that, due to homeostatic regulatory mechanisms, the amount of dietary zinc absorbed 
decreases as intake increases, and plasma zinc concentration is homeostatically controlled within a 
narrow physiological range, therefore this dose response relationship can only be applied to the range 
of intakes used to derive this relationship. The studies included in this meta-analysis were different in a 
number of aspects, such as using various designs, follow-up times, zinc doses, and populations. Nutrients 2012, 4  852 
 
 
Therefore, it is no surprise that, when combining these studies in a meta-analysis, a large heterogeneity 
is observed between the studies (I
2 = 97.6% p = 0.0001). This between-study heterogeneity may be 
caused by methodological factors, such as biological factors, e.g., differences in study population 
characteristics (age, socio-economic status), differences in doses of provided zinc (amount, one or 
more doses per day, study duration). We have considered the dose of zinc provided, study duration, 
age, and supplement type and these factors did not significantly explain the between-study heterogeneity. 
An individual participant data meta-analysis may have provided a more conclusive explanation of the 
between-study heterogeneity in this meta-analysis. However, this type of analysis would involve the 
input of raw individual participant data provided by the original study investigators for re-analysis and 
combination in a pooled analysis and as such would be a major undertaking in terms of time, costs, and 
collaboration. Moreover, an inability to include individual participant data from all relevant studies 
could introduce selection bias. The meta-analytic approach used in this paper is not an attempt to 
accurately describe the biological relation between actual zinc intake and zinc concentrations in blood 
under strict experimental conditions and on an individual level, but rather to simulate a dose-response 
relationship between zinc intake and status that is useful for surveillance studies with a public health 
point of view and, as such, deliberately incorporates the differences between dietary assessment 
methods, laboratory assessment methods and participant characteristics to ensure a broad external 
validity. Thus, the heterogeneity reflects the lack of standardisation of methods and the true 
heterogeneity between study populations and necessarily enters as uncertainty into the application of 
such data for public health purposes [45]. 
The relationship observed between serum/plasma zinc concentration and zinc intake may have been 
weakened by the limitation of this particular biomarker for zinc status. It is well established that 
plasma zinc concentration can fall in response to factors unrelated to zinc status or dietary zinc intake, 
such as infection, inflammation, exercise, stress or trauma. Conversely, tissue catabolism during 
starvation can release zinc into the circulation, causing a transient increase in circulating zinc levels. 
Postprandial plasma zinc concentrations have been reported to fall up to 19% [46]. Twelve studies 
used fasting blood samples in their analyses (usually overnight). Other factors related to the adequacy 
of serum/plasma sampling, such as storage and separation of samples, was often inadequately reported. 
Whilst all studies included in the analysis were undertaken in individuals without chronic disease or 
severe protein-energy malnutrition, other factors such as stress, infection and inflammation may also 
have gone unreported. For example, only three studies screened for parasitic infection [28,30,36]. 
Clearly such confounders have a strong influence on the interpretation of plasma zinc concentrations. 
However, as more sensitive indices of zinc status have yet to be identified, plasma serum zinc remains 
by far the most commonly used biomarker of zinc status [16].  
It is important to note that the majority of studies in our meta-analysis (n = 13 of 18) were 
conducted in countries where participants are likely to have dietary patterns with low-moderate zinc 
bioavailability with higher fibre and phytate content which may have weakened the overall β. 
Although suboptimal zinc status may be caused by inadequate dietary intake of zinc in some cases, 
inhibitors of zinc absorption are likely the most common causative factor [47], and recent evidence in 
adults suggests that the inhibitory effect of dietary factors such as phytate on zinc absorption is likely 
to be much greater than previously recognised [48], although whether this is the case for children is 
less certain [49]. Indeed, a proxy measure for initial nutritional status of participants (zinc Nutrients 2012, 4  853 
 
 
concentration in placebo groups) was found to be a significant effect modifier of β. However as very 
few studies reported baseline zinc or gave details of the concentration of indigestible zinc binding 
ligands in participants’ diets we were unable to investigate this important effect further. 
Zinc was given in combination with other micronutrients including iron in several studies. As iron 
and zinc are known to compete for absorption [50] it is possible that iron supplements may impair 
child zinc status [47]. It is possible therefore that additional supplementation of iron may have reduced 
the effect of zinc supplementation on zinc plasma levels. A review on the interaction between zinc and 
iron in supplementation trials reported that, in the 4 RCTs reviewed, addition of iron to zinc 
supplementation did not affect plasma zinc status in children [51]. As three of the included trials were 
in infants aged 4–6 months and as the iron-regulatory mechanisms of infants may differ before and 
after 9 months of age [52], further studies in older age groups are needed to understand more fully the 
interaction effects of micronutrient supplementation. 
To conduct our meta-analysis some assumptions related to the availability of the required data or 
related to statistical issues had to be made. The meta-analysis required transformations of the intake 
and biomarker data to a common scale, as the studies included in our meta-analyses had different ways 
of reporting the relation between zinc and biomarkers of zinc status in blood. We standardised the 
different ways of reporting by transformation of both the intake and biomarker data to double   
loge-scale, which allowed us to derive a standardised estimate from each study of the regression 
coefficient and its standard error as a basis for comparing these heterogeneously reported results. We 
also assumed a linear relationship on the double loge-scale. This rigorous but flexible transformation 
allowed us to pool β’s and report these as a dose-response relationship between zinc intake and 
serum/plasma zinc concentrations. As compared to a conventional meta-analysis of mean differences 
between high and low exposed subjects, a linear relationship on the double loge-scale with a slope 
lower than 1 allows us to model biomarker levels as a non-linear but monotonic concave function of 
dose, which is considered a more likely shape in biology. The meta-analyses were conducted within 
the context of the EURRECA project as a means to provide additional evidence for underpinning 
reference values for zinc intake of populations [53]. Whether the dose-response relationship, as 
provided in this paper, could be used as either qualitative or quantitative evidence to substantiate the 
daily zinc intake dose necessary to achieve normal or optimal levels of biomarkers for zinc status, 
remains a matter of discussion regarding the cut-off levels for biomarkers of zinc and the predictive 
value of serum/plasma zinc concentration for relevant functional health outcomes such as growth, 
immune function, cognitive function and psychomotor development. 
Due to the wide heterogeneity that exists in the published literature on the relation between zinc 
intake and zinc status, such data cannot be combined in a conventional meta-analysis. Our paper not 
only provides a useful summary of this data in a systematic review, but also demonstrates a new  
meta-analytic approach to summarise all this data while appreciating the heterogeneity of it. The 
mathematical basis of this novel approach has recently been published [41] and is beyond the scope of 
the paper under review here, but in summary, we modelled a dose-response relation as a monotonic 
concave function between zinc intake and biomarkers. This is an innovative way to use all the data 
available, albeit heterogeneous data, to model the dose-response relationship; information which is 
essential when appraising micronutrient recommendations. When more research on zinc intake and Nutrients 2012, 4  854 
 
 
status becomes available, this meta-analytical approach can be improved to strengthen the evidence on 
which we base our zinc recommendations.  
5. Conclusion 
In conclusion, based on 24 estimates among 1722 participants, the results indicate that a doubling 
of zinc increases plasma/serum levels by 9%. Although it is recognised that serum/plasma zinc is a 
somewhat flawed biomarker of zinc status, in the absence of suitable alternatives it remains by far the 
most commonly used method and as such this review provides a valuable source of information for 
those seeking to assess zinc nutriture. As serum/plasma zinc levels are considered intermediates in the 
causal path to health benefits and because the heterogeneity between study results reflects real 
uncertainty in the evidence base, these issues must be taken into account when our dose-response data 
are used as complementary evidence for underpinning zinc reference values. 
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